Application/Control No.: 10/693042
Art Unit: 1647

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Nurit Kalderon

Serial No. : 10/693,042

Filed : October 24, 2003

For : **Beta interferon** for the treatment of chronic spinal cord injury

Examiner : Sandra Wegert

Group Art Unit : 1647

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. §1.8
I hereby certify that this paper is being facsimile transmitted to the United States Patent and Trademark Office on the date indicated below at the facsimile number 571-273-8300.

Nurit Kalderon
Inventor

Nurit Kalderon
Signature

April 17, 2008
Date of Signature

Attention : Examiner Sandra Wegert

Art Unit : 1647

Facsimile No. : 571-273-8300

Pages : 7

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE

Sir:

This is submitted in response to the final Office Action mailed January 24, 2008 and as a follow-up to the April 7, 2008 telephone discussion among the Examiners, Sandra Wegert and Elizabeth Kemmerer, and Richard J. Sterner. At my behest, Dr. Sterner, Registration

No. 35,372, was acting in his capacity as my representative in accordance with 37 C.F.R. § 1.31.

Reconsideration is respectfully requested in view of the amendments and remarks following.

Application/Control No.: 10/693042
Art Unit: 1647

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (currently amended) A method for treating the secondary damage resulting from spinal cord injury, which comprises administering a therapeutically effective amount of ***beta interferon*** or ~~a biosimilar~~ an analogue thereof.

2. (currently amended) The method as recited in claim 1, wherein the ***beta interferon*** or ~~biosimilar~~ analogue thereof is commercially available and is approved by the FDA for the treatment of multiple sclerosis (MS).

3. (currently amended) The method as recited in claim 2, wherein the ***beta interferon*** or ~~biosimilar~~ analogue thereof is administered as prescribed for the treatment of MS.

4. (previously presented) The method as recited in claim 1, wherein Betaseron, Avonex, Rebif or Cinnovex is administered.

5. (original) The method as recited in any one of claims 2-4, wherein the commercially available ***beta interferon*** is administered at the dosage and frequency as prescribed for the treatment of relapsing-remitting MS.

6. (original) The method as recited in claim 5, wherein the ***beta interferon*** is administered starting at about the 11th day or later after injury.

7. (original) The method as recited in claim 5, wherein the ***beta interferon*** is administered starting at the 4th week or later after injury.

8. (currently amended) A method of ~~halting or~~ attenuating the progressive chronic inflammation and demyelination resulting from spinal cord injury, which comprises administering a therapeutically effective amount of ***beta interferon*** or a ~~biosimilar~~ an analogue thereof.

9. (currently amended) The method as recited in claim 8, wherein the ***beta interferon*** or ~~biosimilar~~ analogue thereof is commercially available and is approved by the FDA for the treatment of MS.

10. (currently amended) The method as recited in claim 9, wherein the ***beta interferon*** or ~~biosimilar~~ analogue thereof is administered as prescribed for the treatment of MS.

11. (previously presented) The method as recited in claim 8, wherein Betaseron, Avonex, Rebif or Cinnovex is administered.

12. (original) The method as recited in any one of claims 9-11, wherein the commercially available ***beta interferon*** is administered at the dosage and frequency as prescribed for the treatment of relapsing-remitting MS.

13. (original) The method as recited in claim 12, wherein the ***beta interferon*** is administered starting at about the 11th day or later after injury.

14. (original) The method as recited in claim 12, wherein the ***beta interferon*** is administered starting at the 4th week or later after injury.

15. (currently amended) A method for therapy and rescue of the uninjured neuronal fiber tracts in chronic spinal cord injuries, which comprises administering a therapeutically effective amount of ***beta interferon*** or ~~a biosimilar~~ an analogue thereof.

16. (currently amended) The method as recited in claim 15, wherein the ***beta interferon*** or ~~biosimilar~~ analogue thereof is commercially available and is approved by the FDA for the treatment of MS.

17. (currently amended) The method as recited in claim 16, wherein the ***beta interferon*** or ~~biosimilar~~ analogue thereof is administered as prescribed for the treatment of MS.

18. (previously presented) The method as recited in claim 15, wherein Betaseron, Avonex, Rebif or Cinnovex is administered.

19. (original) The method as recited in any one of claims 16-18, wherein the commercially available ***beta interferon*** is administered at the dosage and frequency as prescribed for the treatment of relapsing-remitting MS.

20. (original) The method as recited in claim 19, wherein the ***beta interferon*** is administered starting at about the 11th day or later after injury.

21. (original) The method as recited in claim 19, wherein the ***beta interferon*** is administered starting at the 4th week or later after injury.

22. (currently amended) A method for repair and rescue of the neurologic function of the uninjured neuronal fiber tracts in chronic spinal cord injuries, which comprises administering a therapeutically effective amount of ***beta interferon*** or ~~a biosimilar~~ an analogue thereof.

23. (currently amended) The method as recited in claim 22, wherein the ***beta interferon*** or ~~biosimilar~~ analogue thereof is commercially available and is approved by the FDA for the treatment of MS.

24. (currently amended) The method as recited in claim 23, wherein the ***beta interferon*** or ~~biosimilar~~ analogue thereof is administered as prescribed for the treatment of MS.

25. (previously presented) The method as recited in claim 22, wherein Betaseron, Avonex, Rebif or Cinnovex is administered.

26. (original) The method as recited in any one of claims 23-25, wherein the commercially available ***beta interferon*** is administered at the dosage and frequency as prescribed for the treatment of relapsing-remitting MS.

27. (original) The method as recited in claim 26, wherein the ***beta interferon*** is administered starting at about the 11th day or later after injury.

28. (original) The method as recited in claim 26, wherein the ***beta interferon*** is administered starting at the 4th week or later after injury.